Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: A cost-effectiveness analysis

Pharmacogenetics and Genomics

Volumn 16, Issue 2, 2006, Pages 139-147

  Meckley, Lisa M ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost effectiveness; Hypertension; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ADDUCIN; ALPHA ADDUCIN; DIURETIC AGENT; GLYCINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DIURETIC THERAPY; EPIDEMIOLOGICAL DATA; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; UNCERTAINTY;

EID: 31344465935     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000189801.96220.82     Document Type: Article

References (55)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
2. Ramsey SD, Neil N, Sullivan SD, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. J Am Board Fam Pract 1999; 12:105-114.
3. Weiss R, Buckley K, Clifford T. Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 1997-2000. Clin Ther 2002; 24:1451-1462.
4. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J. Impact of Clinical Trial Results on National Trends in alpha-Blocker Prescribing, 1996-2002. JAMA 2004; 291:54-62.
5. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA 1998; 279:1813-1816.
6. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349:1353-1357.
7. Wang JG, Staessen JA, Messaggio E, Nawrot T, Fagard R, Hamlyn JM, et al. Salt endogenous ouabain and blood pressure interactions in the general population. J Hypertens 2003; 21:1475-1481.
8. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M, et al. Association of the alpha-adducin locus with essential hypertension. Hypertension 1995; 25:320-326.
9. Castejon AM, Alfieri AB, Hoffmann IS, Rathinavelu A, Cubeddu LX. Alpha-adducin polymorphism, salt sensitivity, nitric oxide excretion, and cardiovascular risk factors in normotensive hispanics. Am J Hypertens 2003; 16:1018-1024.
10. Conway BR, Martin R, McKnight A-J, Savage DA, Brady HR, Maxwell AP. Role of alpha-adducin DNA polymorphisms in the genetic predisposition to diabetic nephropathy. Nephrol Dial Transplant 2004; 19:2019-2024.
11. He X, Zhu DL, Chu SL, Jin L, Xiong MM, Wang GL, et al. Alpha-Adducin gene and essential hypertension in China. Clin Exp Hypertens 2001; 23:579-589.
12. Melander O, Bengtsson K, Orho-Melander M, Lindblad U, Forsblom C, Rastam L, et al. Role of the Gly460Trp polymorphism of the alpha-adducin gene in primary hypertension in Scandinavians. J Hum Hypertens 2000; 14:43-46.
13. Morrison AC, Bray MS, Folsom AR, Boerwinkle E. ADD1 460W allele associated with cardiovascular disease in hypertensive individuals. Hypertension 2002; 39:1053-1057.
14. Province MA, Arnett DK, Hunt SC, Leiendecker-Foster C, Eckfeldt JH, Oberman A, et al. Association between the [alpha]-adducin gene and hypertension in the HyperGEN study. Am J Hypertens 2000; 13:710-718.
15. Schork NJ, Chakravarti A, Thiel B, Fornage M, Jacob HJ, Cai R, et al. Lack of association between a biallelic polymorphism in the adducin gene and blood pressure in whites and African Americans. Am J Hypertens 2000; 13:693-698.
16. Shin MH, Chung EK, Kim HN, Park KS, Nam HS, Kweon SS, et al. Alpha-adducin Gly460Trp polymorphism and essential hypertension in Korea. J Korean Med Sci 2004; 19:812-814.
17. Wang J-G, Staessen JA, Barlassina C, Fagard R, Kuznetsova T, Struijker-Boudier HA, et al. Association between hypertension and variation in the alpha- and beta-adducin genes in a white population. Kidney Int 2002; 62:2152-2159.
18. Ranade K, Hsuing AC, Wu KD, Chang MS, Chen YT, Hebert J, et al. Lack of evidence for an association between alpha-adducin and blood pressure regulation in Asian populations. Am J Hypertens 2000; 13:704-709.
19. Li Y, Thijs L, Kuznetsova T, Zagato L, StruijkerBoudier H, Bianchi G, et al. Cardiovascular risk in relation to alpha-adducin Gly460Trp polymorphism and systolic pressure: a prospective population study. Hypertension 2005; 46:527-532.
20. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287:1680-1689.
21. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41:398-403.
22. Microsoft: Microsoft Office Excel. Redmond, WA, Microsoft Corporation, 2003.
23. Gold MRSJ, Russell LB, Weinstein MC (eds). Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
24. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-298.
25. American Heart Association: Heart Disease and Stroke Statistics - 2003 Update. Dallas, TX, American Heart Association, 2002.
26. National Vital Statistics Report. National Center for Health Statistics, 2002.
27. Nease RF Jr, Owens DK. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making 1994; 14:382-392.
28. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme. A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000; 132:780-787.
29. Consumer Price Index for All Urban Consumers (CPI-U) US City Average, by expenditure category and commodity and service group. Washington, DC, National Bureau of Labor Statistics, 2005.
30. Genelex: Pharmacogenetics Personalizing Medicine today! 2003.
31. DNAdirect: DNAdirect: Your Genes in Context, 2004.
32. Drug Topics Red Book. Montvale, NJ, Medical Economics Co. Inc., 2004.
33. Association AM. 2004 Clinical Diagnostic Laboratory Fee Schedule.
34. Association AM. 2004 National Physician Fee Schedule Relative Value File. 2003.
35. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996; 27:1459-1466.
36. Eisenstein EL, Shaw LK, Anstrom KJ, Nelson CL, Hakim Z, Hasselblad V, et al. Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care 2001; 39:824-835.
37. @Risk. Newfield, NY, Palisade Corporation, 2002.
38. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5:157-177.
39. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17:479-500.
40. Simon SR, Majumdar SR, Prosser LA, Salem-Schatz S, Warner C, Kleinman K, et al. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. Am J Med 2005; 118:521-528.
41. Wu J, Kraja AT, Oberman A, Lewis CE, Ellison RC, Arnett DK, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens 2005; 18:935-942.
42. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
43. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26:917-932.
44. Lehmann DF, Medicis JJ. A pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services. J Clin Pharmacol 1998; 38:783-791.
45. Siegel D, Lopez J, Meier J, Goldstein MK, Lee S, Brazill BJ, et al. Academic detailing to improve antihypertensive prescribing patterns. Am J Hypertens 2003; 16:508-511.
46. Mol PG, Wieringa JE, Nannanpanday PV, Gans RO, Degener JE, Laseur M, et al. Improving compliance with hospital antibiotic guidelines: a time-series intervention analysis. J Antimicrob Chemother 2005; 55:550-557.
47. Javitt JC, Steinberg G, Locke T, Couch JB, Jacques J, Juster I, et al. Using a claims data-based sentinel system to improve compliance with clinical guidelines: results of a randomized prospective study. Am J Manag Care 2005; 11:93-102.
48. Peshkin BN, Schwartz MD, Isaacs C, Hughes C, Main D, Lerman C. Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 2002; 11:1115-1118.
49. Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 2003; 118:201-209.
50. Schwartz MD, Kaufman E, Peshkin BN, Isaacs C, Hughes C, DeMarco T, et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003; 21:4034-4041.
51. Derdeyn CP, Powers WJ. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease. Stroke 1996; 27:1944-1950.
52. Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997; 126:337-346.
53. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995; 10:321-330.
54. Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. Eur Heart J 1991; 12:694-699.
55. Larson N, Hutchinson R, Boerwinkle E. Lack of association of 3 functional gene variants with hypertension in African Americans. Hypertension 2000; 35:1297-1300.